Home GPCR & G Protein GLP-1 Receptor

GLP-1 Receptor

Other GPCR & G Protein Related Inhibitors

Hedgehog/Smoothened PKA CGRP Receptor Endothelin Receptor S1P Receptor Cannabinoid Receptor SGLT Opioid Receptor GPR CCR
Cat.No. Product Name Information Product Use Citations Product Validations
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961) is a non-peptide agonist that activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
bioRxiv, 2024, nan
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
Frontiers in Endocrinology, June 25, 2024, 1395028
bioRxiv, December 17, 2024, nan
Diabetes, December 1, 2025, 2375-2389
P1237New Survodutide Survodutide (BI 456906) is a potent, selective GCGR/GLP‑1R dual agonist with an EC50 of 0.52 nM and 0.33 nM in CHO‑K1 cells, respectively. It exerts robust anti‑obesity efficacy by increasing energy expenditure and decreasing food intake.
P1273New Ecnoglutide（XW003） Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity.
E1827 AZD5004 (ECC5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.
P1278New Brenipatide Brenipatide (LY-3537031) is a dual GLP-1/GIP receptor agonist with the potential to be used in addiction and psychiatric indications, alongside standard metabolic/obesity studies.
E6682New CT-996(RO7795081，RG6652） CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity.
P1274New Ribupatide Ribupatide (HRS9531) is an oral dual GLP‑1/GIP receptor agonist that demonstrates potent glycemic control and clinically meaningful weight‑loss efficacy in obesity and type 2 diabetes trials.
P1230 Retatrutide (LY3437943) Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.